UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 281,036 Shares of Haemonetics Co. (NYSE:HAE)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its stake in shares of Haemonetics Co. (NYSE:HAE - Free Report) by 65.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 147,087 shares of the medical instruments supplier's stock after selling 281,036 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.29% of Haemonetics worth $11,485,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. Janney Montgomery Scott LLC acquired a new position in Haemonetics during the fourth quarter worth $402,000. KBC Group NV raised its stake in shares of Haemonetics by 54.6% in the fourth quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier's stock valued at $157,000 after acquiring an additional 712 shares during the last quarter. Pacer Advisors Inc. raised its stake in shares of Haemonetics by 36.1% in the fourth quarter. Pacer Advisors Inc. now owns 10,104 shares of the medical instruments supplier's stock worth $789,000 after acquiring an additional 2,680 shares during the last quarter. Boston Trust Walden Corp lifted its holdings in Haemonetics by 13.1% during the 4th quarter. Boston Trust Walden Corp now owns 915,722 shares of the medical instruments supplier's stock worth $71,500,000 after buying an additional 106,114 shares in the last quarter. Finally, Empowered Funds LLC acquired a new position in Haemonetics during the 4th quarter valued at about $319,000. 99.67% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Bank of America cut shares of Haemonetics from a "neutral" rating to an "underperform" rating and decreased their price objective for the company from $95.00 to $68.00 in a report on Friday, February 7th. Barrington Research lowered their target price on Haemonetics from $108.00 to $95.00 and set an "outperform" rating on the stock in a research report on Friday, February 7th. Raymond James reiterated a "strong-buy" rating and set a $105.00 price target (down previously from $115.00) on shares of Haemonetics in a report on Friday, May 9th. JMP Securities reiterated a "market outperform" rating and set a $100.00 target price on shares of Haemonetics in a research note on Tuesday, May 20th. Finally, Wall Street Zen downgraded Haemonetics from a "buy" rating to a "hold" rating in a research report on Tuesday, May 13th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Haemonetics has a consensus rating of "Moderate Buy" and an average price target of $97.89.

Haemonetics Price Performance

NYSE:HAE traded up $0.05 during trading hours on Wednesday, hitting $69.71. 462,322 shares of the company's stock traded hands, compared to its average volume of 678,483. The business's fifty day simple moving average is $63.77 and its two-hundred day simple moving average is $69.92. Haemonetics Co. has a 52 week low of $55.30 and a 52 week high of $94.99. The firm has a market cap of $3.35 billion, a P/E ratio of 27.44, a P/E/G ratio of 1.11 and a beta of 0.32. The company has a quick ratio of 2.55, a current ratio of 3.97 and a debt-to-equity ratio of 1.35.

Haemonetics (NYSE:HAE - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.02. Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. The company had revenue of $330.60 million for the quarter, compared to analysts' expectations of $329.38 million. During the same period in the prior year, the business earned $0.90 earnings per share. Haemonetics's revenue for the quarter was down 3.5% compared to the same quarter last year. On average, research analysts anticipate that Haemonetics Co. will post 4.55 earnings per share for the current fiscal year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.